So because of the activity that we saw in artistry one and mucosa melanoma, um You know, the decision was made to pursue this further and that indication, and we call melanoma because it is um a rare disease, it is given some accommodations by the the FDA and so one of those accommodations is um orphan drug designation, right, which provides benefits to the development program in terms of access to the FDA. Um, and, um, some financial considerations as well. Given the small market size, should this drug be approved. Again, this is, you know, we're talking maybe 1500 cases a year in the United States. Um, all told new diagnosis, so it's a very small market share, um. I think those sorts of accommodations are really, really important for the rare cancer field, um, as, as you might imagine, um. I think it's, it's a clearer path in terms of financial decisions for pharma to go after uh the the more common cancers, lung cancer, prostate cancer, colon cancer, breast cancer, uh, certainly, and those incentives are a little bit less with the less common cancers. And yet, um, Um, More often than not, the, the less common cancers are the ones that um are in um perhaps more significant need for some of these novel therapies. And so this is, you know, this is a big issue I think in in the entire cancer field, um, particularly as we Understand that the different molecular subsets of the various diseases we're treating, uh, and as we subdivide and subdivide and subdivide cancers into different histologic subsets or molecular subsets, um, With frequently different biologies and different responses to therapies and different clinical courses, I think this problem is going to become only more important. Um, And um And kind of studying those subsets and understanding that biology, even in a rare indication, I think can um accelerate development and perhaps more common diseases.
Presenter
